P&G Hygiene Appoints Srividya Srinivasan as Executive Director and CFO

P&G Hygiene and Health Care Limited has appointed Ms. Srividya Srinivasan as Executive Director and Chief Financial Officer effective July 1, 2026, following the resignation of Mr. Gaurav Bhartia as Chief Financial Officer. The Board of Directors approved the leadership changes at its meeting held on May 28, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The appointments and resignations are part of a broader restructuring within the organization.

Leadership Transitions

Mr. Gaurav Bhartia ceased to be the Chief Financial Officer of the Company with effect from June 30, 2026, due to a change in assignment at P&G. Concurrently, Mr. Ghanashyam Hegde resigned as Company Secretary and Compliance Officer effective June 30, 2026, to assume a regional role as Vice President & Associate General Counsel - Market Operations, India, Middle East, Turkey & Africa effective July 1, 2026. The Board approved the re-designation of Mr. Hegde as Non-Executive Director of the Company effective July 1, 2026.

Profile of Incoming CFO

Ms. Srividya Srinivasan has been appointed as Executive Director and Chief Financial Officer for a term of five years, subject to the approval of the shareholders at the ensuing 62nd Annual General Meeting. She is a Bachelor of Computer Science Engineering from Anna University, Coimbatore, and holds a Master of Business Administration in Finance from the University of Virginia, Darden School of Business. Ms. Srinivasan brings 20 years of experience, having joined P&G in 2005 and worked across various markets including the USA, Latin America, and the Philippines.

The Company confirmed that Ms. Srinivasan is not debarred from holding the office of Director by SEBI, MCA, or any other authority and is not disqualified under Section 164 of the Companies Act, 2013. It was further disclosed that she does not hold any shares in the Company and is not related to any of the Directors.

Summary of Key Changes

The following table outlines the key personnel changes approved by the Board at its meeting held on May 28, 2026:

Name	Role	Effective Date	Reason
Mr. Gaurav Bhartia	Resignation as Chief Financial Officer	June 30, 2026	Change in assignment at P&G
Mr. Ghanashyam Hegde	Resignation as Company Secretary and Compliance Officer	June 30, 2026	Moving to regional role at P&G
Mr. Ghanashyam Hegde	Re-designation as Non-Executive Director	July 1, 2026	Board approval
Ms. Srividya Srinivasan	Appointment as Executive Director and CFO	July 1, 2026	Leadership succession

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.59%	+0.31%	-6.39%	-24.48%	-32.19%	-27.45%

Procter & Gamble Hygiene and Health Care Limited reported a 19% increase in net profit to ₹857 crore for the fiscal year ended March 31, 2026, driven by product mix, productivity, and efficiency. Sales for the year stood at ₹4,290 crore, remaining flat compared to the indexed comparable period. The board has recommended a total dividend of ₹255 per share, comprising a final dividend of ₹60 and an interim dividend of ₹195, subject to shareholder approval.

The company changed its financial year end from June 30 to March 31 effective last year, resulting in the previous financial year covering a nine-month period from July 1, 2024, to March 31, 2025. Consequently, the current year's performance is indexed against the comparable 12-month period in the prior year to ensure accurate assessment.

Q4 Financial Performance

For the fourth quarter ended March 31, 2026, revenue stood at ₹941 crore compared to ₹992 crore in the same period last year, reflecting a decline. Net profit for the quarter came in at ₹153 crore versus ₹156 crore year-on-year. Despite the revenue pressure, EBITDA improved on a year-on-year basis, rising to ₹217 crore from ₹211 crore, while the EBITDA margin expanded to 23.1% from 21.24% in the same period last year, reflecting improved operational efficiency.

The following table summarises the key Q4 metrics:

Metric:	Q4 FY26	Q4 FY25 (YoY)
Revenue:	₹941 crore	₹992 crore
Net Profit:	₹153 crore	₹156 crore
EBITDA:	₹217 crore	₹211 crore
EBITDA Margin:	23.1%	21.24%

Full-Year Financial Performance

The company's earnings per share (EPS) for the year increased to ₹263.86 from ₹196.11 in the prior period. Total comprehensive income for FY26 was ₹861 crore. Cash and cash equivalents as of March 31, 2026, stood at ₹5,570 crore, compared to ₹4,664 crore a year ago. The table below presents the full-year financial summary:

Financial Metric (₹ in Lakhs):	Year Ended March 31, 2026	Previous Year (9 Months) Ended March 31, 2025
Revenue from operations:	4,29,042	3,37,442
Total income:	4,33,289	3,41,176
Total expenses:	3,16,626	2,54,960
Profit before tax:	1,16,663	86,216
Profit for the period:	85,650	63,659
Earnings per share (Basic) (₹):	263.86	196.11

Strategic Initiatives

V Kumar, Managing Director, emphasized the company's focus on meaningful innovation across its feminine care and healthcare portfolios. During the year, the company amplified communication for the Whisper Period Panty and upgraded formulations for Whisper Choice and Whisper Bindazzz Nights. In healthcare, the upgraded Vicks VapoRub formulation with Eucalyptus Oil, Menthol, and Camphor continued to deliver All-Night Relief.

Dividend Declaration

The board recommended a final dividend of ₹60 per equity share of face value ₹10 each. Including the interim dividend of ₹195 per share, the total payout for the fiscal amounts to ₹255 per share. The final dividend is scheduled to be paid on or before September 18, 2026, pending approval by members at the 62nd Annual General Meeting.